Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ACADIA Pharmaceuticals ( (ACAD) ) has shared an announcement.
On March 3, 2026, Acadia Pharmaceuticals’ board appointed Jonathan M. Poole as a Class II director to fill a vacancy and as a member of the Audit Committee, with his initial term running through the 2027 annual shareholder meeting. The move strengthens the company’s governance structure and audit oversight at a time when board expertise and independence are key considerations for shareholders in the biopharmaceutical industry.
Under Acadia’s non-employee director compensation policy, Poole will receive prorated annual cash retainers for board and audit committee service, along with an initial equity grant of $200,000 that vests over three years and an additional prorated annual equity grant of $95,300 that vests over one year. Beginning with the 2026 annual meeting, he will be eligible for recurring annual equity awards with a $400,000 target value, aligning his compensation with shareholder interests through long-term incentive structures and standard indemnification protections.
The most recent analyst rating on (ACAD) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.
Spark’s Take on ACAD Stock
According to Spark, TipRanks’ AI Analyst, ACAD is a Neutral.
The score is driven primarily by improved fundamentals (profitability and a strong, low-debt balance sheet) and constructive forward guidance for continued growth. This is tempered by weak technicals (price below key moving averages with negative MACD) and some near-term execution/regulatory and margin risks highlighted on the earnings call.
To see Spark’s full report on ACAD stock, click here.
More about ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative medicines, particularly in neuroscience-related indications. The company operates in the highly regulated healthcare sector, where board composition and governance practices are closely watched by investors and other stakeholders.
Average Trading Volume: 1,503,324
Technical Sentiment Signal: Buy
Current Market Cap: $3.84B
Find detailed analytics on ACAD stock on TipRanks’ Stock Analysis page.